Pangea's Sdamlo Reimagines Heart Drug for Vulnerable Patients

FORT LAUDERDALE, Fla. – April 15, 2026

Pangea Pharmaceuticals has launched Sdamlo™, a novel formulation of the widely prescribed cardiovascular drug amlodipine, aiming to solve a critical and often overlooked challenge in medicine: administering pills to those who cannot swallow them. The U.S. launch introduces the first and only FDA-approved amlodipine powder for oral solution, designed specifically for pediatric, geriatric, and other patient populations who struggle with traditional tablets.

The new product enters a massive, multi-billion dollar market for amlodipine, a cornerstone therapy for hypertension and cardiovascular disease. However, instead of competing with low-cost generics on price, Pangea is targeting a significant unmet need, offering a solution that prioritizes patient safety, ease of administration, and caregiver confidence.

Addressing a Widespread, Overlooked Challenge

While a simple pill may seem straightforward, for millions of Americans, it represents a daily obstacle. Difficulty swallowing, or dysphagia, is a pervasive issue. Recent data suggests that it affects approximately 1 in 17 adults in the United States, or over 15 million people. The prevalence is dramatically higher in vulnerable groups; dysphagia impacts up to 33% of older adults and can affect more than half of all residents in nursing homes. It is also a common complication in pediatric patients with developmental conditions.

For these individuals, a standard amlodipine tablet is not a viable option. The common workaround—crushing tablets and mixing them with food or water—is fraught with risk. This unlicensed practice can lead to inaccurate dosing, altered drug efficacy, and an unpleasant taste that reduces patient compliance. For the more than half a million Americans who rely on enteral feeding tubes, crushed pills pose a significant risk of clogging the tube, a complication that can lead to interruptions in nutrition and medication, and may require a medical procedure to replace the tube.

Existing alternatives have their own limitations. While pharmacists can compound liquid versions, these formulations are not FDA-approved and can suffer from inconsistencies in potency and stability. In recent years, FDA-approved liquid solutions like Norliqva® and Katerzia® have entered the market, providing a more reliable option than compounding. Sdamlo, however, aims to further refine the administration process.

A Differentiated Solution in a Crowded Market

Pangea Pharmaceuticals is positioning Sdamlo not just as another liquid, but as a thoughtfully designed system for medication delivery. The product is a powder that is reconstituted into an oral solution, a format achieved through a patent-pending lyophilization (freeze-drying) process. This technology ensures the active ingredient is uniformly distributed and stable.

The key differentiator lies in its unit-dose packaging. Each dose comes in a pre-measured container, eliminating the need for measuring, shaking, or stirring. This "no guess" dosing is designed to ensure patients receive the exact prescribed amount every time, a critical factor for a potent cardiovascular medication.

“Sdamlo reflects our commitment to creating better products from proven molecules and bringing them to market in a way that always puts patients first,” said Tony LaViola, CEO and Co-Founder of Pangea Pharmaceuticals, in a statement. “We are focused on identifying meaningful gaps in care and delivering solutions that improve access, simplify administration, and support better outcomes.”

Furthermore, the formulation is free of alcohol, preservatives, and sucralose, enhancing its suitability for sensitive pediatric patients or those with specific allergies or dietary restrictions. Unlike some liquid medications, Sdamlo does not require refrigeration, simplifying storage for both families at home and large-scale institutional facilities.

Streamlining Care in Hospitals and Long-Term Facilities

The operational benefits of Sdamlo are particularly significant for institutional settings like hospitals and long-term care facilities, where efficiency and safety are paramount. In these high-pressure environments, nurses and pharmacists are constantly managing complex medication schedules for dozens or even hundreds of patients.

The manual process of crushing pills or preparing compounded liquids is time-consuming and introduces multiple points for potential error. A unit-dose, ready-to-administer product like Sdamlo can dramatically streamline this workflow. It reduces preparation time, minimizes the risk of cross-contamination, and provides a standardized, reliable method of administration that is consistent from one caregiver to the next.

For patients with feeding tubes, the ready-to-administer liquid format is particularly beneficial, enabling precise, consistent enteral delivery without the common issue of tube clogging. According to medical experts in geriatric and institutional care, such innovations are critical for improving patient safety, as they can help reduce medication errors and adverse events associated with improper administration. This contributes not only to better patient outcomes but also to greater operational efficiency for the healthcare system.

A Strategic Play for a Proven Molecule

The launch of Sdamlo represents a calculated business strategy for Pangea Pharmaceuticals. Rather than attempting to develop a new blockbuster drug from scratch—a process that is notoriously long and expensive—the company is focusing on re-innovating established, proven molecules. By taking a drug like amlodipine, whose safety and efficacy are well-documented over decades, and creating a new delivery system that solves a real-world problem, Pangea can carve out a valuable niche in a mature market.

This strategy is underpinned by a key partnership with Brillian Pharma, the developer of the proprietary technology behind Sdamlo. “This collaboration reflects a shared commitment to advancing differentiated formulations of widely prescribed therapies while addressing challenges associated with traditional solid oral dosage forms,” stated Dr. Nolan Wang, Co-Founder and Chief Technology Officer of Brillian Pharma.

This model allows Pangea to build a portfolio of specialized products that, while not serving the entire patient population for a given drug, provide significant value to a specific, underserved segment. For Pangea, Sdamlo is a foundational product that demonstrates the viability of its platform and commercial strategy.

“We are building a thoughtful and intentional portfolio centered on solutions that make a meaningful difference in patients’ lives,” LaViola added. The company has indicated it is actively evaluating additional opportunities for collaboration and pipeline expansion. Sdamlo began its rollout in multiple strengths in March, with Pangea planning to launch additional strengths in the coming months to fully serve the needs of its target patient populations.